Cabazitaxel Patent Expiration
Cabazitaxel is used for treating metastatic castration-resistant prostate cancer after prior treatment with docetaxel by administering cabazitaxel in combination with prednisone or prednisolone. It was first introduced by Sanofi Aventis Us Inc
Cabazitaxel Patents
Given below is the list of patents protecting Cabazitaxel, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Jevtana Kit |
US10583110 (Pediatric) | Antitumoral Use Of Cabazitaxel | Apr 27, 2031 | Sanofi Aventis Us |
| Jevtana Kit |
US10716777 (Pediatric) | Antitumoral Use Of Cabazitaxel | Apr 27, 2031 | Sanofi Aventis Us |
| Jevtana Kit |
US12453712 (Pediatric) | Antitumoral Use Of Cabazitaxel | Apr 27, 2031 | Sanofi Aventis Us |
| Jevtana Kit |
US8927592 (Pediatric) | Antitumoral use of cabazitaxel | Apr 27, 2031 | Sanofi Aventis Us |
| Jevtana Kit | US10583110 | Antitumoral use of cabazitaxel | Oct 27, 2030 | Sanofi Aventis Us |
| Jevtana Kit | US10716777 | Antitumoral use of cabazitaxel | Oct 27, 2030 | Sanofi Aventis Us |
| Jevtana Kit | US12453712 | Antitumoral Use Of Cabazitaxel | Oct 27, 2030 | Sanofi Aventis Us |
| Jevtana Kit | US8927592 | Antitumoral use of cabazitaxel | Oct 27, 2030 | Sanofi Aventis Us |
| Jevtana Kit |
US7241907 (Pediatric) | Acetone solvate of dimethoxy docetaxel and its process of preparation |
Jun 10, 2026
(Expired) | Sanofi Aventis Us |
| Jevtana Kit | US7241907 | Acetone solvate of dimethoxy docetaxel and its process of preparation |
Dec 10, 2025
(Expired) | Sanofi Aventis Us |
| Jevtana Kit |
US5847170 (Pediatric) | Taxoids, their preparation and pharmaceutical compositions containing them |
Sep 26, 2021
(Expired) | Sanofi Aventis Us |
| Jevtana Kit | US5847170 | Taxoids, their preparation and pharmaceutical compositions containing them |
Mar 26, 2016
(Expired) | Sanofi Aventis Us |
| Jevtana Kit | US6331635 | Taxoids, their preparation and pharmaceutical compositions containing them |
Mar 26, 2016
(Expired) | Sanofi Aventis Us |
| Jevtana Kit | US6372780 | Methods of treating cell lines expressing multidrug resistance P-glycoprotein |
Mar 26, 2016
(Expired) | Sanofi Aventis Us |
| Jevtana Kit | US6387946 | Methods for treating pathological conditions of abnormal cell proliferation |
Mar 26, 2016
(Expired) | Sanofi Aventis Us |
| Jevtana Kit | US5438072 | Taxoid-based compositions |
Nov 22, 2013
(Expired) | Sanofi Aventis Us |
| Jevtana Kit | US5698582 | Compositions containing taxane derivatives |
Jul 03, 2012
(Expired) | Sanofi Aventis Us |
Cabazitaxel's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Cabazitaxel:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
